Diabetic Ketoacidosis Associated With Alpelisib Treatment Of Metastatic Breast Cancer
Open Access
- 1 November 2020
- journal article
- Published by Elsevier BV in AACE Clinical Case Reports
- Vol. 6 (6), e349-e351
- https://doi.org/10.4158/accr-2020-0452
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerAnnals of Oncology, 2020
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2019
- Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin LymphomasClinical Lymphoma Myeloma and Leukemia, 2019
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)Annals of Oncology, 2018
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast CancerClinical Cancer Research, 2017
- Insulin Receptor Signaling in Normal and Insulin-Resistant StatesCold Spring Harbor Perspectives in Biology, 2014
- Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar SyndromeDiabetes Spectrum, 2002